The global Robotic Assisted Endovascular Systems Market is poised for significant growth, with a projected market size of US$ 94.0 million in 2023 and an anticipated CAGR of 8.6% throughout the forecast period, propelling it to a valuation of US$ 214.7 million by 2033.
The Robotic Assisted Endovascular Systems Market involves the application of cutting-edge robotic technology in endovascular procedures, which are minimally invasive treatments conducted within blood vessels. These procedures primarily address a range of conditions, including cardiovascular diseases, peripheral artery diseases, aneurysms, and various vascular disorders.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17601
Several factors are driving the escalating demand for Robotic Assisted Endovascular Systems:
- Growing Disease Prevalence: The increasing incidence of cardiovascular diseases, peripheral artery diseases, and other vascular disorders is fueling the demand for advanced treatment options.
- Robotic Technology Advancements: Ongoing developments in robotic technology are equipping robotic-assisted endovascular systems with enhanced capabilities.
- Surgeon Adoption: An increasing number of surgeons are recognizing the potential benefits of integrating robotic systems into endovascular procedures, seeking state-of-the-art equipment and technology to enhance their efficiency and improve patient outcomes.
The Robotic Assisted Endovascular Systems Market’s growth signifies a promising shift towards advanced, minimally invasive treatments for vascular disorders, providing both patients and healthcare professionals with innovative and efficient solutions.
Key Players:
- Siemens Healthcare
- Stereotaxis, Inc
Key Developments in the Robotic Assisted Endovascular Systems Market:
- Cathbot Robot Co., Ltd. (Shanghai Cathbot™), developed a vascular interventional surgical robot. In August 2022, the company announced the conclusion of its clinical trial, making it the first robotic system to have finished a multicenter clinical trial in China, for vascular intervention. Further, the company is a collaboration between French company Robocath S.A.S (Robocath), R-ONETM and Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot™)
- In December 2018, 48 CorPath GRX Systems were deployed in hospitals around the United States, and four were installed abroad.
Robotic Assisted Endovascular Systems Market Segmentation:
By Product:
- Systems
- Software & Services
By Application:
- Neurosurgery
- Percutaneous coronary intervention
- Peripheral vascular interventions
- Electrophysiology procedures
By End User:
- Hospital
- Cath Lab
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East & Africa
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-17601
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube